1 Min Read
** Canadian biotech's U.S.-listed shares up about 25 pct at 67 cents
** Says data from mid-stage study of experimental drug reolysin in combination with chemotherapy gemcitabine suggests increase in median overall survival
** Data indicates combination can also nearly double 1-year survival rates, raise 2-year survival rates by 5 times, compared with gemcitabine alone - COO Matt Coffey
** Up to Thursday's close, stock had fallen nearly 24 pct since April 29, when drug developer announced European regulator had granted reolysin "orphan drug status"